CXCR2 and neoplasm: Flow cytometry analysis of tumor-infiltrating leukocytes (TIL) collected at the experimental endpoint revealed a significant decrease in CXCR2+ CD11b+ Ly6G+ cells in tumors from mice that received SX-682-medicated feed (Fig. 5d-e), and a significant increase in granzyme B expression in CD8+ T cells in the tumors treated with combination therapy compared to all other groups.